<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35354901</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>NU-9 improves health of hSOD1<sup>G93A</sup> mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone.</ArticleTitle><Pagination><StartPage>5383</StartPage><MedlinePgn>5383</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5383</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-09332-4</ELocationID><Abstract><AbstractText>Even though amyotrophic lateral sclerosis (ALS)&#xa0;is a disease of the upper and lower motor neurons, to date none of the compounds in clinical trials have been tested for improving the health of diseased upper motor neurons (UMNs). There is an urgent need to develop preclinical assays that include UMN health as a readout. Since ALS is a complex disease, combinatorial treatment strategies will be required to address the mechanisms perturbed in patients. Here, we describe a novel in vitro platform that takes advantage of an UMN reporter line in which UMNs are genetically labeled with fluorescence and have misfolded SOD1 toxicity. We report that NU-9,&#xa0;an analog of the cyclohexane-1,3-dione family of compounds, improves the health of UMNs with misfolded SOD1 toxicity more effectively&#xa0;than riluzole or edaravone, -the only two FDA-approved ALS drugs to date-. Interestingly, when NU-9 is applied in combination with riluzole or edaravone, there is an additive effect on UMN health, as they extend longer axons and display enhanced branching and arborization, two important characteristics of healthy UMNs in vitro.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gen&#xe7;</LastName><ForeName>Bar&#x131;&#x15f;</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautam</LastName><ForeName>Mukesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helmold</LastName><ForeName>Benjamin R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko&#xe7;ak</LastName><ForeName>Nuran</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nay</LastName><ForeName>Aksu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goshu</LastName><ForeName>Gashaw M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Northwestern University, Evanston, IL, 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Northwestern University, Evanston, IL, 60208, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, IL, 60208, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hande Ozdinler</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Developmental Therapeutics, Northwestern University, Evanston, IL, 60208, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG061708</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG061708</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="Y">Riluzole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35354901</ArticleId><ArticleId IdType="pmc">PMC8967818</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-09332-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-09332-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Genc B, et al. Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS. Sci. Rep. 2017;7:41765. doi: 10.1038/srep41765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41765</ArticleId><ArticleId IdType="pmc">PMC5292972</ArticleId><ArticleId IdType="pubmed">28165465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, et al. MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J.. Neuroinflam. 2019;16:196. doi: 10.1186/s12974-019-1589-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1589-y</ArticleId><ArticleId IdType="pmc">PMC6822373</ArticleId><ArticleId IdType="pubmed">31666087</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, et al. Evidence for an early innate immune response in the motor cortex of ALS. J Neuroinflammation. 2017;14:129. doi: 10.1186/s12974-017-0896-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0896-4</ArticleId><ArticleId IdType="pmc">PMC5485686</ArticleId><ArticleId IdType="pubmed">28651542</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, et al. Mitochondria, ER, and nuclear membrane defects reveal early mechanisms for upper motor neuron vulnerability with respect to TDP-43 pathology. Acta Neuropathol. 2019;137:47&#x2013;69. doi: 10.1007/s00401-018-1934-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1934-8</ArticleId><ArticleId IdType="pmc">PMC6339587</ArticleId><ArticleId IdType="pubmed">30450515</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Ozdinler PH, Kiernan MC, Vucic S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat. Rev. Neurol. 2016;12:651&#x2013;661. doi: 10.1038/nrneurol.2016.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.140</ArticleId><ArticleId IdType="pubmed">27658852</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Gozutok O, Ozdinler PH. Complexity of generating mouse models to study the upper motor neurons: Let us shift focus from mice to neurons. Int. J. Mol. Sci. 2019 doi: 10.3390/ijms20163848.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20163848</ArticleId><ArticleId IdType="pmc">PMC6720674</ArticleId><ArticleId IdType="pubmed">31394733</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Ozdinler PH. Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discov. Today. 2014;19:441&#x2013;449. doi: 10.1016/j.drudis.2013.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2013.10.014</ArticleId><ArticleId IdType="pmc">PMC4000750</ArticleId><ArticleId IdType="pubmed">24171950</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervishi I, Ozdinler PH. Incorporating upper motor neuron health in ALS drug discovery. Drug Discov. Today. 2018;23:696&#x2013;703. doi: 10.1016/j.drudis.2018.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2018.01.027</ArticleId><ArticleId IdType="pmc">PMC5849515</ArticleId><ArticleId IdType="pubmed">29331501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade? CNS Neurosci. Ther. 2011;17:4&#x2013;31. doi: 10.1111/j.1755-5949.2009.00116.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00116.x</ArticleId><ArticleId IdType="pmc">PMC6493865</ArticleId><ArticleId IdType="pubmed">20236142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986. doi: 10.1016/j.neuropharm.2020.107986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.107986</ArticleId><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Beltran S, Bakkouche SE, Couratier P. Therapeutic news in ALS. Rev. Neurol. (Paris) 2021;177:544&#x2013;549. doi: 10.1016/j.neurol.2020.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2020.12.003</ArticleId><ArticleId IdType="pubmed">33781562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignani S, Majoral JP, Desaphy JF, Lentini G. From riluzole to dexpramipexole via substituted-benzothiazole derivatives for amyotrophic lateral sclerosis disease treatment: case studies. Molecules. 2020 doi: 10.3390/molecules25153320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25153320</ArticleId><ArticleId IdType="pmc">PMC7435757</ArticleId><ArticleId IdType="pubmed">32707914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS ONE. 2015;10:e0140316. doi: 10.1371/journal.pone.0140316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0140316</ArticleId><ArticleId IdType="pmc">PMC4607459</ArticleId><ArticleId IdType="pubmed">26469273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 2008;213:448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing, G. &amp; Edaravone, A. L. S. S. G. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet neurology16, 505&#x2013;512, 10.1016/S1474-4422(17)30115-1 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, et al. Edaravone inhibits the induction of iNOS gene expression at transcriptional and posttranscriptional steps in murine macrophages. Shock. 2008;30:734&#x2013;739. doi: 10.1097/SHK.0b013e318173ea0b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318173ea0b</ArticleId><ArticleId IdType="pubmed">18496239</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, et al. Edaravone prevents iNOS expression by inhibiting its promoter transactivation and mRNA stability in cytokine-stimulated hepatocytes. Nitric Oxide Biol. Chem. Offic. J. Nitric Oxide Soc. 2008;18:105&#x2013;112. doi: 10.1016/j.niox.2007.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2007.11.003</ArticleId><ArticleId IdType="pubmed">18078833</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotr. Lateral Sclerosis Offic. Publ. World Federat. Neurol. Res. Group Motor Neuron Diseases. 2006;7:241&#x2013;245. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2013;1431. doi: 10.1016/s0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1996;39:147&#x2013;157. doi: 10.1002/ana.410390203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390203</ArticleId><ArticleId IdType="pubmed">8967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50:62&#x2013;66. doi: 10.1212/wnl.50.1.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.50.1.62</ArticleId><ArticleId IdType="pubmed">9443458</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis Offic. Publ. World Federat. Neurol. Res. Group Motor Neuron Diseases. 2008;9:4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg MC, Halang L, Woods I, Coughlan KS, Prehn JHM. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotr. Lateral Sclerosis Frontotemp. Degener. 2018;19:438&#x2013;445. doi: 10.1080/21678421.2017.1407796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1407796</ArticleId><ArticleId IdType="pubmed">29221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Sung M, Rutkove SB. Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice. PLoS ONE. 2013;8:e65976. doi: 10.1371/journal.pone.0065976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0065976</ArticleId><ArticleId IdType="pmc">PMC3675066</ArticleId><ArticleId IdType="pubmed">23762454</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin S. Preclinical research: Make mouse studies work. Nature. 2014;507:423&#x2013;425. doi: 10.1038/507423a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/507423a</ArticleId><ArticleId IdType="pubmed">24678540</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarotto GB, et al. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1(G93A)) of ALS. J. Neuroinflammat. 2019;16:218. doi: 10.1186/s12974-019-1598-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1598-x</ArticleId><ArticleId IdType="pmc">PMC6857328</ArticleId><ArticleId IdType="pubmed">31727149</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann. Clin. Transl. Neurol. 2014;1:996&#x2013;1005. doi: 10.1002/acn3.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.141</ArticleId><ArticleId IdType="pmc">PMC4284125</ArticleId><ArticleId IdType="pubmed">25574474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AL, et al. Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2021;54:6237&#x2013;6255. doi: 10.1111/ejn.15422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.15422</ArticleId><ArticleId IdType="pubmed">34390052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y, et al. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2019;97:607&#x2013;619. doi: 10.1002/jnr.24368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24368</ArticleId><ArticleId IdType="pubmed">30565312</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma T, Kobayashi S, Sato H, Fujii J. Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro. Exp. Cell Res. 2019;384:111592. doi: 10.1016/j.yexcr.2019.111592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2019.111592</ArticleId><ArticleId IdType="pubmed">31479686</ArticleId></ArticleIdList></Reference><Reference><Citation>Benmohamed R, et al. Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Offic. Publ. World Federt. Neurol. Res. Group Motor Neuron Diseases. 2011;12:87&#x2013;96. doi: 10.3109/17482968.2010.522586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.522586</ArticleId><ArticleId IdType="pmc">PMC8131116</ArticleId><ArticleId IdType="pubmed">21073276</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. Bioorg. Med. Chem. 2012;20:1029&#x2013;1045. doi: 10.1016/j.bmc.2011.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2011.11.039</ArticleId><ArticleId IdType="pmc">PMC3259267</ArticleId><ArticleId IdType="pubmed">22189273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS. ACS Med. Chem. Lett. 2012;3:584&#x2013;587. doi: 10.1021/ml3000963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ml3000963</ArticleId><ArticleId IdType="pmc">PMC3402085</ArticleId><ArticleId IdType="pubmed">22837812</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto G, Kim S, Morimoto RI. Huntingtin and mutant SOD1 form aggregate structures with distinct molecular properties in human cells. J. Biol. Chem. 2006;281:4477&#x2013;4485. doi: 10.1074/jbc.M509201200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M509201200</ArticleId><ArticleId IdType="pubmed">16371362</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto G, Stojanovic A, Holmberg CI, Kim S, Morimoto RI. Structural properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. J. Cell Biol. 2005;171:75&#x2013;85. doi: 10.1083/jcb.200504050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200504050</ArticleId><ArticleId IdType="pmc">PMC2171239</ArticleId><ArticleId IdType="pubmed">16216923</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, et al. Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology. Clin. Transl. Med. 2021;11:e336. doi: 10.1002/ctm2.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.336</ArticleId><ArticleId IdType="pmc">PMC7898037</ArticleId><ArticleId IdType="pubmed">33634973</ArticleId></ArticleIdList></Reference><Reference><Citation>Burg T, et al. Absence of subcerebral projection neurons is beneficial in a mouse model of amyotrophic lateral sclerosis. Ann. Neurol. 2020;88:688&#x2013;702. doi: 10.1002/ana.25833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25833</ArticleId><ArticleId IdType="pmc">PMC7540428</ArticleId><ArticleId IdType="pubmed">32588450</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasvoina MV, et al. eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model. J. Neurosci. Offic. J. Soc. Neurosci. 2013;33:7890&#x2013;7904. doi: 10.1523/JNEUROSCI.2787-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2787-12.2013</ArticleId><ArticleId IdType="pmc">PMC3963467</ArticleId><ArticleId IdType="pubmed">23637180</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ali H, Lemmon VP, Bixby JL. Phenotypic screening of small-molecule inhibitors: Implications for therapeutic discovery and drug target development in traumatic brain injury. Methods Mol. Biol. 2016;1462:677&#x2013;688. doi: 10.1007/978-1-4939-3816-2_37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3816-2_37</ArticleId><ArticleId IdType="pubmed">27604745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, et al. Quantifying amyloid beta (Abeta)-mediated changes in neuronal morphology in primary cultures: Implications for phenotypic screening. J. Biomol. Screen. 2012;17:835&#x2013;842. doi: 10.1177/1087057112441972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1087057112441972</ArticleId><ArticleId IdType="pubmed">22473881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman SP, Bang AG. High-throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell-derived neurons. Disease Models Mech. 2018 doi: 10.1242/dmm.031906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.031906</ArticleId><ArticleId IdType="pmc">PMC5894944</ArticleId><ArticleId IdType="pubmed">29361516</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlon DS. Drug discovery for hearing loss: Phenotypic screening of chemical compounds on primary cultures of the spiral ganglion. Hear Res. 2017;349:177&#x2013;181. doi: 10.1016/j.heares.2016.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heares.2016.07.019</ArticleId><ArticleId IdType="pubmed">27496256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat. Neurosci. 2006;9:1371&#x2013;1381. doi: 10.1038/nn1789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1789</ArticleId><ArticleId IdType="pubmed">17057708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristanovic D, Milosevic NT, Stulic V. Application of modified Sholl analysis to neuronal dendritic arborization of the cat spinal cord. J. Neurosci. Methods. 2006;158:212&#x2013;218. doi: 10.1016/j.jneumeth.2006.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2006.05.030</ArticleId><ArticleId IdType="pubmed">16814868</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenen J. The dendritic organization of the human spinal cord: the dorsal horn. Neuroscience. 1982;7:2057&#x2013;2087. doi: 10.1016/0306-4522(82)90120-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(82)90120-8</ArticleId><ArticleId IdType="pubmed">7145088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholl DA. Dendritic organization in the neurons of the visual and motor cortices of the cat. J. Anat. 1953;87:387&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1244622</ArticleId><ArticleId IdType="pubmed">13117757</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Gozutok O, Kocak N, Ozdinler PH. The timing and extent of motor neuron vulnerability in ALS correlates with accumulation of misfolded SOD1 protein in the cortex and in the spinal cord. Cells. 2020 doi: 10.3390/cells9020502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020502</ArticleId><ArticleId IdType="pmc">PMC7072754</ArticleId><ArticleId IdType="pubmed">32098365</ArticleId></ArticleIdList></Reference><Reference><Citation>Molyneaux, B. J., Arlotta, P. &amp; Macklis, J. D. Molecular development of corticospinal motor neuron circuitry. Novartis Found.. Symp.288, 3&#x2013;15; discussion 15&#x2013;20, 96&#x2013;18, doi:10.1016/j.expneurol.2006.02.074 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18494249</ArticleId></ArticleIdList></Reference><Reference><Citation>Molyneaux BJ, Arlotta P, Menezes JR, Macklis JD. Neuronal subtype specification in the cerebral cortex. Nat. Rev. Neurosci. 2007;8:427&#x2013;437. doi: 10.1038/nrn2151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2151</ArticleId><ArticleId IdType="pubmed">17514196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdinler PH, et al. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G(9)(3)A transgenic ALS mice. J. Neurosci. Offic. J. Soc. Neurosci. 2011;31:4166&#x2013;4177. doi: 10.1523/JNEUROSCI.4184-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4184-10.2011</ArticleId><ArticleId IdType="pmc">PMC3643523</ArticleId><ArticleId IdType="pubmed">21411657</ArticleId></ArticleIdList></Reference><Reference><Citation>Charcot JM, Marie P. Deux nouveaux cas de sclerose lat&#xe9;rale amyotrophique suivis d'autopsie. Archives De Neurologie. 1885;10:1&#x2013;35.</Citation></Reference><Reference><Citation>Fischer LR, et al. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The, "dying-back" phenomenon of motor neurons in ALS. J. Mol. Neurosci. 2011;43:470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou SM, Norris FH. Amyotrophic lateral sclerosis: Lower motor neuron disease spreading to upper motor neurons. Muscle Nerve. 1993;16:864&#x2013;869. doi: 10.1002/mus.880160810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880160810</ArticleId><ArticleId IdType="pubmed">8332139</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Bruijn LI, Shefner JM. ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment. Neurology. 2019;93:66&#x2013;71. doi: 10.1212/WNL.0000000000007695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007695</ArticleId><ArticleId IdType="pmc">PMC6656654</ArticleId><ArticleId IdType="pubmed">31171646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdinler PH. Expanded access: Opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases. FEBS J. 2021;288:1457&#x2013;1461. doi: 10.1111/febs.15529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15529</ArticleId><ArticleId IdType="pmc">PMC7887139</ArticleId><ArticleId IdType="pubmed">32805742</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, et al. Absence of alsin function leads to corticospinal motor neuron vulnerability via novel disease mechanisms. Hum. Mol. Genet. 2016;25:1074&#x2013;1087. doi: 10.1093/hmg/ddv631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv631</ArticleId><ArticleId IdType="pmc">PMC4764190</ArticleId><ArticleId IdType="pubmed">26755825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>